481 related articles for article (PubMed ID: 29775598)
41. EIF2A-dependent translational arrest protects leukemia cells from the energetic stress induced by NAMPT inhibition.
Zucal C; D'Agostino VG; Casini A; Mantelli B; Thongon N; Soncini D; Caffa I; Cea M; Ballestrero A; Quattrone A; Indraccolo S; Nencioni A; Provenzani A
BMC Cancer; 2015 Nov; 15():855. PubMed ID: 26542945
[TBL] [Abstract][Full Text] [Related]
42. A combination of the metabolic enzyme inhibitor APO866 and the immune adjuvant L-1-methyl tryptophan induces additive antitumor activity.
Yang HJ; Yen MC; Lin CC; Lin CM; Chen YL; Weng TY; Huang TT; Wu CL; Lai MD
Exp Biol Med (Maywood); 2010 Jul; 235(7):869-76. PubMed ID: 20558841
[TBL] [Abstract][Full Text] [Related]
43. Targeting the NAD Salvage Synthesis Pathway as a Novel Therapeutic Strategy for Osteosarcomas with Low NAPRT Expression.
Franceschini N; Oosting J; Tamsma M; Niessen B; Bruijn IB; van den Akker B; Kruisselbrink AB; Palubeckaitė I; Bovée JVMG; Cleton-Jansen AM
Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34200964
[TBL] [Abstract][Full Text] [Related]
44. Nicotinamide phosphoribosyltransferase (NAMPT) activity is essential for survival of resting lymphocytes.
Pittelli M; Cavone L; Lapucci A; Oteri C; Felici R; Niccolai E; Amedei A; Chiarugi A
Immunol Cell Biol; 2014 Feb; 92(2):191-9. PubMed ID: 24275857
[TBL] [Abstract][Full Text] [Related]
45. Detection and pharmacological modulation of nicotinamide mononucleotide (NMN) in vitro and in vivo.
Formentini L; Moroni F; Chiarugi A
Biochem Pharmacol; 2009 May; 77(10):1612-20. PubMed ID: 19426698
[TBL] [Abstract][Full Text] [Related]
46. Optical Redox Imaging of Treatment Responses to Nampt Inhibition and Combination Therapy in Triple-Negative Breast Cancer Cells.
Podsednik A; Jiang J; Jacob A; Li LZ; Xu HN
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34070254
[TBL] [Abstract][Full Text] [Related]
47. Expression patterns of nicotinamide phosphoribosyltransferase and nicotinic acid phosphoribosyltransferase in human malignant lymphomas.
Olesen UH; Hastrup N; Sehested M
APMIS; 2011 Apr; 119(4-5):296-303. PubMed ID: 21492230
[TBL] [Abstract][Full Text] [Related]
48. Chinese medicine Bu-Fei decoction attenuates epithelial-mesenchymal transition of non-small cell lung cancer via inhibition of transforming growth factor β1 signaling pathway in vitro and in vivo.
He XR; Han SY; Li XH; Zheng WX; Pang LN; Jiang ST; Li PP
J Ethnopharmacol; 2017 May; 204():45-57. PubMed ID: 28412214
[TBL] [Abstract][Full Text] [Related]
49. A preclinical study on the rescue of normal tissue by nicotinic acid in high-dose treatment with APO866, a specific nicotinamide phosphoribosyltransferase inhibitor.
Olesen UH; Thougaard AV; Jensen PB; Sehested M
Mol Cancer Ther; 2010 Jun; 9(6):1609-17. PubMed ID: 20515945
[TBL] [Abstract][Full Text] [Related]
50. The bile acid receptor GPBAR1 (TGR5) is expressed in human gastric cancers and promotes epithelial-mesenchymal transition in gastric cancer cell lines.
Carino A; Graziosi L; D'Amore C; Cipriani S; Marchianò S; Marino E; Zampella A; Rende M; Mosci P; Distrutti E; Donini A; Fiorucci S
Oncotarget; 2016 Sep; 7(38):61021-61035. PubMed ID: 27409173
[TBL] [Abstract][Full Text] [Related]
51. LGR5 Is a Gastric Cancer Stem Cell Marker Associated with Stemness and the EMT Signature Genes NANOG, NANOGP8, PRRX1, TWIST1, and BMI1.
Wang B; Chen Q; Cao Y; Ma X; Yin C; Jia Y; Zang A; Fan W
PLoS One; 2016; 11(12):e0168904. PubMed ID: 28033430
[TBL] [Abstract][Full Text] [Related]
52. EphA2 promotes epithelial-mesenchymal transition through the Wnt/β-catenin pathway in gastric cancer cells.
Huang J; Xiao D; Li G; Ma J; Chen P; Yuan W; Hou F; Ge J; Zhong M; Tang Y; Xia X; Chen Z
Oncogene; 2014 May; 33(21):2737-47. PubMed ID: 23752181
[TBL] [Abstract][Full Text] [Related]
53. EphA2 affects the sensitivity of oxaliplatin by inducing EMT in oxaliplatin-resistant gastric cancer cells.
Wen Q; Chen Z; Chen Z; Chen J; Wang R; Huang C; Yuan W
Oncotarget; 2017 Jul; 8(29):47998-48011. PubMed ID: 28624791
[TBL] [Abstract][Full Text] [Related]
54. Molecular mechanism of Poria cocos combined with oxaliplatin on the inhibition of epithelial-mesenchymal transition in gastric cancer cells.
Wang N; Liu D; Guo J; Sun Y; Guo T; Zhu X
Biomed Pharmacother; 2018 Jun; 102():865-873. PubMed ID: 29710543
[TBL] [Abstract][Full Text] [Related]
55. SPARC enhances 5-FU chemosensitivity in gastric cancer by modulating epithelial-mesenchymal transition and apoptosis.
Ma J; Ma Y; Chen S; Guo S; Hu J; Yue T; Zhang J; Zhu J; Wang P; Chen G; Liu Y
Biochem Biophys Res Commun; 2021 Jun; 558():134-140. PubMed ID: 33910127
[TBL] [Abstract][Full Text] [Related]
56. Chemopotentiating effects of a novel NAD biosynthesis inhibitor, FK866, in combination with antineoplastic agents.
Pogrebniak A; Schemainda I; Azzam K; Pelka-Fleischer R; Nüssler V; Hasmann M
Eur J Med Res; 2006 Aug; 11(8):313-21. PubMed ID: 17052966
[TBL] [Abstract][Full Text] [Related]
57. Migration of gastric cancer is suppressed by recombinant Newcastle disease virus (rL-RVG) via regulating α7-nicotinic acetylcholine receptors/ERK- EMT.
Bu X; Zhang A; Chen Z; Zhang X; Zhang R; Yin C; Zhang J; Zhang Y; Yan Y
BMC Cancer; 2019 Oct; 19(1):976. PubMed ID: 31640627
[TBL] [Abstract][Full Text] [Related]
58. Targeting epithelial-to-mesenchymal transition with Met inhibitors reverts chemoresistance in small cell lung cancer.
Cañadas I; Rojo F; Taus Á; Arpí O; Arumí-Uría M; Pijuan L; Menéndez S; Zazo S; Dómine M; Salido M; Mojal S; García de Herreros A; Rovira A; Albanell J; Arriola E
Clin Cancer Res; 2014 Feb; 20(4):938-50. PubMed ID: 24284055
[TBL] [Abstract][Full Text] [Related]
59. Target enzyme mutations are the molecular basis for resistance towards pharmacological inhibition of nicotinamide phosphoribosyltransferase.
Olesen UH; Petersen JG; Garten A; Kiess W; Yoshino J; Imai S; Christensen MK; Fristrup P; Thougaard AV; Björkling F; Jensen PB; Nielsen SJ; Sehested M
BMC Cancer; 2010 Dec; 10():677. PubMed ID: 21144000
[TBL] [Abstract][Full Text] [Related]
60. The role of hERG1 ion channels in epithelial-mesenchymal transition and the capacity of riluzole to reduce cisplatin resistance in colorectal cancer cells.
Fortunato A
Cell Oncol (Dordr); 2017 Aug; 40(4):367-378. PubMed ID: 28593575
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
